Nitroxyl inhibits breast tumor growth and angiogenesis

International Journal of Cancer

Volumn 122, Issue 8, 2008, Pages 1905-1910

  Norris, Andrew J ^a   Sartippour, Maryam R ^a   Lu, Ming ^a   Park, Taylor ^a   Rao, Jian Yu ^a   Jackson, Matthew I ^b   Fukuto, Jon M ^a   Brooks, Mai N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angeli's salt; Angiogenesis; Breast cancer; Glycolysis; Nitroxyl

Indexed keywords

ANGELI SALT; DECOMPOSED ANGELI SALT; ESTROGEN RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NITROGEN OXIDE; NITROXYL; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; NITRITE; OXYHYPONITRITE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EMBRYO; GLYCOLYSIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FEMALE; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; NICK END LABELING; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, SCID; NITRITES; NITROGEN OXIDES; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 40349085661     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23305     Document Type: Article

References (31)

1. Ignarro LJ. Nitric oxide: biology and pathobiology. San Diego: Academic Press, 2000.1003 p.
2. Wong PSY, Hyun J, Fukuto JM, Shirota FN, DeMaster EG, Shoeman DW, Nagasawa HT. Reaction between S-nitrosothiols and thiols: Generation of nitroxyl (HNO) and subsequent chemistry. Biochemistry 1998;37:5362-71.
3. Fukuto JM, Bartberger MD, Dutton AS, Paolocci N, Wink DA, Houk KN. The physiological chemistry and biological activity of nitroxyl (HNO): The neglected, misunderstood, and enigmatic nitrogen oxide. Chem Res Toxicol 2005;18:790-801.
4. Paolocci N, Katori T, Champion HC, John ME, Miranda KM, Fukuto JM, Wink DA, Kass DA. Positive inotropic and lusitropic effects of HNO/NO in failing hearts: Independence from β-adrenergic signaling. Proc Natl Acad Sci USA 2003;100:5537-42.
5. Pagltaro P, Mancardi D, Rastaldo R, Penna C, Gatullo D, Miranda KM, Feelisch M, Wink DA, Kass DA, Paolocci N. Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med 2003;34:33-43.
6. Demaster EG, Redfern B, Nagasawa HT. Mechanisms of inhibition of aldehyde dehydrogenase by nitroxyl, the active metabolite of the alcohol deterrent agent cyanamide. Biochem Pharmacol 1998;55:2007-15.
7. Bartberger MD, Fukuto JM, Houk KN. On the acidity and reactivity of HNO in aqueous solution and biological systems. Proc Natl Acad Sci USA 2001;98:2194-8.
8. Vaeaenaenen AJ, Salmenperae P, Hukkanen M, Rauhala P, Kankuri E. Cathepsin B is a differentiation-resistant target for nitroxyl (HNO) in THP-1 monocyte/macrophages. Free Radic Biol Med 2006;41:120-31.
9. Lopez BE, Rodriguez CE, Pribadi M, Cook N, Shinyashiki M, Fukuto JM. Inhibition of yeast glycolysis by nitroxyl (HNO): mechanism of HNO toxicity and implications to HNO biology. Arch Biochem Biophys 2005;442:140-8.
10. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-46.
11. Xu R, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Deating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005;65:613-21.
12. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
13. Lu M, Zhang L, Maul RS, Sartippour MR, Norris A, Whitelegge J, Rao J, Brooks MN. The novel gene EG-1 stimulates cellular proliferation. Cancer Res 2005;65:6159-66.
14. Sartippour M, Heber D, Lu Q, Ma M, Go VL, Nguyen M. Green tea inhibits breast cancer growth and angiogenesis. Nutr Cancer 2001;40:149-56.
15. Sartippour MR, Pietras R, Marquez-Garban DC, Chen HW, Heber D, Henning SM, Sartippour G, Zhang L, Lu M, Weinberg O, Rao JY, Brooks MN. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis 2006;27:2424-33.
16. Tomlinson J, Barsky SH, Nelson S, Singer S, Pezeshki B, Lee MC, Eilber F, Nguyen M. Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 1999;5:3516-22.
17. Wisser KC, Schauerte JA, Burke DT, Galecki A, Chen S, Miller RA, Gafni A. Mapping tissue-specific genes correlated with age-dependent changes in protein stability and function. Arch Biochem Biophys 2004;432:58-70.
18. Stoyanovsky DA, Schor NF, Nylander KD, Salama G. Effects of pH on the cytotoxicity of sodium trioxodinitrate (Angeli's salt). J Med Chem 2004;47:210-17.
19. Miranda KM, Nagasawa HT, Toscano JP. Donors of HNO. Curr Top Med Chem 2005;5:649-64.
20. Miranda KM, Dutton AS, Ridnour LA, Foreman CA, Ford E, Paolocci N, Katori T, Tocchetti CG, Mancardi D, Thomas DD, Espey MG, Houk KN, et al. Mechanism of aerobic decomposition of Angeli's salt (sodium trioxodinitrate) at physiological pH. J Am Chem Soc 2005;127:722-31.
21. Donzelli S, Espey MG, Thomas DD, Mancardi D, Tocchetti CG, Ridnour LA, Paolocci N, King SB, Miranda KM, Lazzarino G, Fukuto JM, Wink DA. Discriminating formation of HNO from other reactive nitrogen oxide species. Free Radic Biol Med 2006;40:1056-66.
22. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
23. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337-40.
24. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
25. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Gene Dev 2001;15:2675-56.
26. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002;295:858-61.
27. Nagasawa HT, Kawle SP, Elberling J, DeMaster E, Fukuto JM. Prodrugs of nitroxyl as potential aldehyde dehydrogenase inhibitors vis-a-vis vascular smooth muscle relaxants. J Med Chem 1995;38:1865-71.
28. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 2005;280:41928-39.
29. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature Rev 2004;4:891-9.
30. Bai P, Bakondi E, Szabo E, Gergely P, Szabo C, Virag L. Partial protection by poly(ADP-ribose) polymerase inhibitors from nitroxyl-induced cytotoxity in thymocytes. Free Radic Biol Med 2001;31:1616-23.
31. Hara MR, Snyder SH. Nitric oxide-GAPDH-siah: a novel cell death cascade. Cell Mol Neurobiol 2006;26:525-36.